The combined organic phases were washed with water and evaporated to give the free base of the title compound in 700 g yield.

The reac­ tion mixture was stirred until a clear solution was obtained, then the methylene chloride phase was separated and washed twice with water (2 1).

The solution was slowly cooled under stirring to 5°-10° C. and the precipitate was collected by filtration and dried to give the desired product in 980 g (90%) yield.

Recrystallization from warm (80° C.) 2-propanol (5 1) added activated carbon (10 g) gave after filtration and cooling to 5°-10° C. pure crystals of the title compound.

A method of treating cognitive dysfunction caused by Alzheimer’s disease in a mammal comprising administering an effective amount of the compound according to claim 1.

List of certificates issued by the EDQM Official Announcement - Rapid Implementation on 01/01/2000 Magnesium stearate Isopropyl alcohol Products with risk of transmitting agents of animal spongiform encephalopathies Minimising the risk of transmitting animal spongiform encephalopathy agents via medicinal products (5.2.8) Replacement Production statements for monographs on TSE-risk products Aprotinin Aprotinin concentrated solution Calcium stearate Cholesterol Chymotrypsin Decyl oleate Diethylene glycol monopalmitostearate Erythromycin stearate Ethyl oleate Ethylene glycol monopalmitostearate Glycerol distearate Glycerol mono-oleates Glycerol monostearate 40-55 Hyaluronidase Insulin Macrogol stearate Macrogol stearyl ether Magnesium stearate Parnaparin sodium Propylene glycol monopalmitostearate Stearic acid Stearoyl macrogolglycerides Trypsin Vaccines for human use International Conferences Mycoplasma Testing the Potentialities & Roles of PCR Tests - 13-14 March 2000, Paris, France The Future Face of the European Pharmacopoeia Current Concerns in Pharmaceutical Analysis 9-10 October 2000, Lisbon, Portugal Tetanus Vaccines for Human Use 22-23 June 2000, Strasbourg, France

January 2000 General Information CD-ROM 2000 of the European Pharmacopoeia Press release: Conference in Berlin Conditions of sale of CRS List of CRS adopted in November 1999 Prepublication brochure (June 1999) List of texts published in the June 1999 prepublication brochure List of texts adopted in November 1999 Draft monographs for comment Arnica tincture Assay of human coagulation factor II (2.7...) Assay of human coagulation factor X (2.7...) Azaperone Bovine viral diarrhoea vaccine (inactivated) Canine adenovirus vaccine (live) Caraway oil Carbon dioxide Cetyl palmitate Dihydroergocristine mesilate Diphtheria, tetanus and pertussis (acellular, component) vaccine (adsorbed) Diphtheria, tetanus, pertussis (acellular, component) and haemophilus type b conjugate vaccine (adsorbed) 95 Diphtheria, tetanus, pertussis (acellular, component) and hepatitis B (rDNA) vaccine (adsorbed) Diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine (adsorbed) Framycetin sulphate Gemfibrozil Greater celandine Heptaminol hydrochloride Human coagulation factor VII, freeze-dried Human plasma (pooled and treated for virus inactivation) Human prothrombin complex, freeze-dried Hymecromone Ibuprofen Iodinated (125I) human albumin injection Ioxaglic acid Java tea Levamisole Levamisole hydrochloride Lobeline hydrochloride Marsh mallow leaf Mesterolone Mint oil, dementholised Neomycin sulphate Netilmicin sulphate Nitrous oxide Oak bark Orphenadrine citrate Orphenadrine hydrochloride Phytosterol Pipemidic acid trihydrate Poloxamers Pravastatin sodium Rosemary oil Sage leaf (salvia officinalis) Semi-solid preparations for cutaneous application Sodium perborate trihydrate Star anise Thyme Wild pansy (flowering aerial parts) Zinc stearate © PHARMEUROPA Vol.

The previous edition contained translations in sixteen European languages : Croatian, Danish, Dutch, English, Finnish, French, German, Greek, Italian, Norwegian, Portuguese, Slovak, Slovenian, Spanish, Swedish and Turkish).

Information and orders: Council of Europe European Department for the Quality of Medicines (EDQM) BP 907 - F67029 Strasbourg Cedex 1 tel.

Readers of Pharmeuropa are asked to inform EDQM of their opinion on the need for a test and limit in the light of their experience with mesilate salts.